This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013
There was no evidence in the literature searched pertaining to the clinical or cost-effectiveness of LMWHs versus warfarin for long-term primary prevention of VTE. However, findings from four publications comparing the clinical efficacy and cost-effectiveness of LMWHs versus warfarin for long-term treatment and secondary prevention of VTE suggest that LMWHs may be as effective as warfarin to prevent recurrent VTE, and more effective than warfarin in a specific population of cancer patients, without increasing the risk of bleeding. However, findings should be interpreted in light of the various limitations identified. Despite higher acquisition costs, dalteparin may be cost-effective compared to warfarin in cancer patients; no economic evidence was identified for other individual agents.
Subject indexing assigned by CRD
Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Venous Thrombosis; Warfarin
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published